LabPas CT™ Selected by Qualia Clinical Services for Phase I Clinical Trials

Qualia Clinical Services, a highly regarded division of Holmes Biopharma, has agreed to purchase LabPas CT to automate clinical trials in its recently expanded Phase I facility in Omaha, Nebraska.

"Automating our recently expanded Phase I facility with LabPas CT will enable us to provide our Pharma and Biotech sponsors with top quality, highly efficient, state-of-the-art clinical trials," said Azhar Kalim, Vice President and General Manager.

According to Qualia CEO Dr. Sohail Khattak, “We are committed to helping our clients accelerate their time-to-market. LabPas CT will help us accomplish that.”

John Rosenblum, CEO of Green Mountain Logic, the developer of LabPas CT, added, “It is a pleasure to partner with Qualia. Their understanding of and commitment to improving quality and efficiency through the automation of Phase I trials is unsurpassed.”

Qualia Clinical Services is the sixth highly regarded clinical research organizations this year to select LabPas CT. Others include CEDRA Clinical Research, Acclaim Pharma Research, Advanced Biomedical Research, Arkansas Clinical Research and Nucleus Network.

The rapid success of Qualia's Phase I facility, which opened in the fall of 2006, necessitated the recent addition of 10,000 square feet. The clinic now boasts a total of 33,000 square feet, a bed capacity of over 160 beds and more than 120 professional staff. Additionally, administrative, operational and recreational areas were completely redesigned to better serve clients and study participants. Qualia Clinical Services is changing lives for the better by providing its partners in the clinical research industry the full capabilities to complete early and late phase clinical trials. A full service contract research organization, Qualia has state-of-the-art clinical operations in Omaha, Nebraska, Toronto, Canada and Kiev, Ukraine.

Green Mountain Logic, located in Montpelier, Vermont, provides powerful, reliable, easy to use, targeted technology solutions to the life science industry. GML’s LabPas CT product comprehensively manages Phase I clinical trials, from recruiting through export to EDC. Unique in its intuitive use and adaptability to individual study protocols, LabPas CT increases margins, improves compliance and expands capabilities. In the last year, seven highly regarded CROs have selected LabPas CT to automate their Phase I studies.